This phase I trial studies the side effects and best dose of oxidative phosphorylation
inhibitor IACS-010759 (IACS-010759) in treating patients with lymphoma that has come back
(relapsed) or does not respond to treatment (refractory) or solid tumors that have spread to
other places in the body (advanced/metastatic) or cannot be removed by surgery
(unresectable). IACS-010759 may stop the growth of cancer or tumor cells by blocking some of
the enzymes needed for cell growth.